Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Washington University School of Medicine84 enrolled

Overview

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Subarachnoid Hemorrhage

Interventions

Brief LEVOTHER

Levetiracetam 1000mg BID x 3 days for prophylaxis

Extended LEVOTHER

Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age \>18 years of age 2. Diagnosis of spontaneous SAH Exclusion Criteria: 1. SAH secondary to trauma or arteriovenous malformation 2. Early death (defined as death within 3 days of presentation) 3. Known allergy to levetiracetam 4. Know seizure history on chronic AEDs 5. Pregnancy 6. Current incarceration

Locations (1)

Barnes-jewish Hospital

St Louis, Missouri, United States

Outcomes

Primary Outcomes

In-hospital Seizures

from admission to In-hospital seizures after aSAH

Time frame: from hospital admission to hospital discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.